Page 127 - NobleCon19revC2_Neat

Lisata Therapeutics, Inc.

SELECTED FINANCIAL ITEMS LSTA

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (6.54) (6.84) (6.88) (5.96) (26.22)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (5.99) (6.19) (4.03) (5.26) (21.47)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 73.03 66.33 62.37 58.09 58.09
Cash & Short Term Investments 32.15 28.16 23.69 32.43 32.43
% of Assets 44% 42% 38% 56% 56%
Current Assets -Total 71.88 65.30 61.42 57.23 57.23
% of Assets 98% 98% 98% 99% 99%
Total Liabilities 6.71 5.62 4.65 5.39 5.39
% of Assets 9% 8% 7% 9% 9%
Current Liabilities - Total 6.38 5.29 4.36 5.13 5.13
% of Assets 9% 8% 7% 9% 9%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 66.32 60.70 57.71 52.70 52.70
% of Assets 91% 92% 93% 91% 91%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (6.47) (8.20) (4.18) (3.58) (22.43)
Net Cash Flow - Investing 7.11 4.29 (0.73) 12.25 22.92
Net Cash Flow - Financing 0.01 (0.09) 0.45 (0.01) 0.38

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference